Surrozen, Inc./DE (SRZN) stock intrinsic value fair value estimate & owner earnings analysis

Surrozen is a clinical-stage biopharmaceutical company developing therapies based on its proprietary Wnt-pathway ("SWAP") antibody platform. Its most advanced wholly-owned program, SZN-8141, targets diabetic macular edema and wet age-related macular degeneration. The company has no approved products and generates no product sales. Its only revenue comes from a 2022 research collaboration and license agreement with Boehringer Ingelheim covering a separate program, SZN-413, which has produced two milestone payments to date ($10 million in 2024 and $5 million in early 2026); Boehringer Ingelheim now bears further development costs and expenses for that program. Because none of Surrozen's pipeline has reached FDA approval, we assign no value to any drug candidate or to any future payment that depends on an event that has not yet happened -- including the $95.1 million second tranche of a 2025 private placement that only closes if the FDA clears the company's IND application for SZN-8141, a decision expected on or before October 31, 2026. Instead we value Surrozen the way we would value any company holding a depleting pool of cash: what it has today, less the present value of the losses it will keep incurring while it continues to fund research. As of its most recent balance sheet the company held roughly $100 million in cash with no outstanding borrowed debt. Operating losses ran at an annualized pace of roughly $40 million over the first half of 2026, up from about $30 million for all of 2025, as spending ramped on SZN-8141's path toward an IND filing. At that pace the current cash funds a bit over two years of operations before new, currently unsecured financing would be needed. Management states that existing cash, together with financings completed in early 2026, is sufficient to fund operations for at least the next twelve months, and the auditors have not raised any going-concern doubt. Because the cash on the balance sheet is largely destined to be spent on research we are not crediting with any value, our estimate of what the shares are worth today is a small fraction of cash per share, reflecting mainly the time-value benefit of spending that cash gradually rather than all at once -- not any value for the pipeline itself: - Bear case: spending accelerates further (toward roughly $48 million a year) as multiple ophthalmology programs are pushed forward; the runway shortens to under two years, and financing needed near the end of it would likely be highly dilutive. Value is at or near zero. - Base case: losses continue at roughly the pace seen in the first half of 2026 (about $40 million a year). Value is approximately $0.75 per share. - Bull case: spending eases back toward the lower pace seen in 2025 (roughly $25-30 million a year) as the heaviest IND-enabling costs move behind the company. Value is approximately $1.00 per share. We checked whether the higher 2026 spending pace was still accelerating quarter to quarter, which would argue for a worse base case; it was not -- quarterly operating expenses were roughly flat between the first and second quarters of 2026, supporting rather than undermining the base-case assumption. A large balance-sheet liability tied to the 2025 private placement (a "tranche liability," which reached roughly $196 million by mid-2026) is a non-cash accounting entry tracking the changing fair value of the company's obligation to issue more shares if the FDA milestone is met. It swings the reported net income figure sharply from quarter to quarter but is not money owed to lenders and would be settled with new shares alongside a cash inflow, not a cash outflow, so we have not treated it as debt. Given how much of the current cash value depends on spending assumptions that have not yet played out, and how binary the near-term FDA decision is, the margin-of-safety price is set at a large discount to our base-case estimate -- around $0.30 per share. FDA clearance of the SZN-8141 IND application and closing of the additional $95.1 million financing would meaningfully extend the runway and reduce the risk of a near-term dilutive raise. Note on complexity: Surrozen's capital structure includes multiple classes of warrants and a two-tranche private placement with embedded, fair-value-accounted features. These materially affect reported net income from quarter to quarter but do not affect the company's actual cash burn.